New setback for Astra Zeneca

Published:

New setback for Astra Zeneca
Photo: Pontus Lundahl/TT

Astra Zeneca has suffered a new setback, according to a press release from the Swedish-British pharmaceutical giant.

Datopotamab deruxtecan (Dato-DXD) – a preparation for the treatment of patients with cancer developed with Japanese Daiichi Sankyo – has, according to a phase-3 study comparing Dato-DXD's effect with the effects of chemotherapy in breast cancer, not shown any statistically confirmed positive effects regarding the patients' lifespan.

Earlier in September, a separate study also did not show any significant impact on survival for lung cancer patients.

Astra Zeneca's share has risen by 18 percent since the turn of the year.

Loading related articles...

Tags

Author

TTT
By TTEnglish edition by Sweden Herald, adapted for our readers

More news

Loading related posts...